[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malaria-transmission\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malaria-transmission":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100622856","assessing-the-feasibility-of-combining-dihydroartemisinin-piperaquine-and-primaquine-for-malaria-mass-drug-administration-in-high-endemic-communities-in-the-eastern-region-of-ghana-100622856",false,"NCT07389057","Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana","Implementation Research to Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana","Inclusion Criteria:\n\n* must be aged 3 months and above and\n* be resident in the communities for the period of the study,\n* completed and signed a consent form from the parent or guardian of children below 18 years\n* Completed and signed assent for 12-17 years old children.\n* Completed and signed consent for those from age 18 years and above.\n\nExclusion Criteria:\n\n* Pregnant women\n* individual with a life-threatening illness (excluding malaria)\n* less than 10Kg body weight (or less than 1 year old)\n* individuals who had experienced adverse effects related to primaquine or\n* known to be G6PD deficient .",true,"ALL","3 Months",{"count":20,"type":21},9000,"ESTIMATED","INTERVENTIONAL",[24],"NA","Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections. In a mass testing, treatment and tracking (MTTT) study, more than 75% of people in target communities were reached, leading to a 24% reduction in asymptomatic malaria after one year. However, rapid diagnostic tests (RDTs) can miss very low-level infections, meaning some infected individuals are not treated and can continue to spread malaria.\n\nA pilot malaria mass drug administration (MDA) study using artemether-lumefantrine (AL) in the Eastern Region of Ghana showed a very large reduction (over 95%) in parasite carriage after repeated rounds of treatment. Despite this success, malaria infections later fluctuated, possibly because some parasites remained in mosquitoes and because mature gametocytes-the parasite stage responsible for transmission-are not fully eliminated by standard malaria medicines.\n\nTo better interrupt malaria transmission, this study will use MDA with dihydroartemisinin-piperaquine (DHAP) combined with a single low dose of primaquine (PQ), which targets these transmission stages. The intervention will be given to the whole community every two months (six times per year) and compared with the current standard malaria control measures.\n\nThe study will examine whether this approach reduces malaria parasite carriage, whether malaria returns after treatment stops, and whether repeated MDA affects malaria drug resistance markers in the population. This two-year implementation research will generate practical evidence to guide national malaria policy in Ghana and inform the potential use of MDA in other malaria-endemic African countries.",[27,28,29,30],"Malaria Asymptomatic Parasitaemia","Malaria Falciparum","Malaria Infection","Malaria Transmission",[32,33,34,35,36],"Malaria","Mass drug administration","Ghana","Feasibility","Implementation Research","RECRUITING","2026-01-30",{"date":40,"type":41},"2026-02-05","ACTUAL",{"date":43,"type":41},"2023-11-01",{"date":45,"type":21},"2026-11-30",{"name":47,"class":48},"Noguchi Memorial Institute for Medical Research","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":49},"100622724","long-acting-spatial-emanators--repellents-laser-100622724","NCT07387341","Long-acting Spatial Emanators \u002F Repellents (LASER)","Long-acting Spatial Emanators \u002F Repellents (LASER) vs Indoor Residual Spraying (IRS) in Western Kenya: a Cluster-randomised Trial","LASER","The inclusion criteria are:\n\n1. Child aged 1-15 years\n2. Usual resident (a person who has been residing in the survey area for at least the past 4 months) who was present in the sampled household on the night before the survey\n3. Agreement of adult or parent\u002Fguardian (of children) to provide informed consent\n4. Agreement of child aged 12 years or older to provide assent\n\nThe exclusion criterion is:\n\n1\\. Child not at home after 3 attempts","1 Year","15 Years",{"count":61,"type":21},22815,[24],"Malaria is a major problem in western Kenya, particularly around Lake Victoria. Whilst current prevention methods like bed nets and vaccines help to reduce malaria burden, additional tools are needed to better protect communities from malaria. The investigators will test a new technology called LASER Guardian™, which are devices that release chemicals to keep mosquitoes away from homes. The investigators will conduct a large study involving 69 villages in western Kenya over two years. Each village will be randomly chosen to receive one of three approaches: the new LASER devices, indoor residual spraying with insecticide (a method already known to work), or the standard prevention methods currently used. All villages will continue to receive the usual malaria prevention tools provided by the Kenyan government, including bed nets and vaccines. In villages receiving LASER, the investigators will install 2-3 small device inside structures once a year for two years. In villages receiving IRS, the investigators will spray the inside walls of homes with insecticide once a year for two years. The investigators want to find out if the LASER devices can reduce malaria better than current methods alone, and whether they work as well as indoor spraying. To do this, the investigators will carry out surveys of the community every six months over two years (four rounds in total), testing about 4,485 children between ages 1 and 15 from approximately 3,450 households in each survey to see how many have malaria. The investigators will also work with local health clinics to track malaria cases, study mosquitoes to understand how the interventions affect them, talk with community members about their experiences, and calculate the costs of these different approaches. This study will help us understand whether LASER tool can effectively protecting against malaria in Kenya and other African countries where malaria is common.",[30,65,32],"Malaria Prevention",[67,68,69,70],"spatial repellents","spatial emanators","Indoor Residual Spraying","Kenya","NOT_YET_RECRUITING","2026-01-27",{"date":74,"type":41},"2026-02-04",{"date":76,"type":21},"2026-01-17",{"date":78,"type":21},"2028-04-30",{"name":80,"class":48},"Liverpool School of Tropical Medicine",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":49},"100583853","phase-1-experimental-malaria-infection-of-healthy-malaria-naive-adults-by-mosquito-bite-with-the-genetically-modified-plasmodium-falciparum-nf54igp3-gap-100583853","NCT06881732","Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54\u002FiGP3 GAP","iGP3-SWITCH","INCLUSION CRITERIA:\n\n* Able and willing to complete the informed consent process\n* Available for the entire planned study duration\n* Male or Female\n* Aged 18 to 55 years\n* Willing to have blood samples collected, stored indefinitely and used for research purposes\n* Willing to defer blood donations for at least six months after the EoS visit (D180)\n* Agreement to adhere to specific Lifestyle Considerations throughout study duration\n\nClinical Criteria:\n\n* Total body weight ≥ 50 kg, and a body mass index (BMI) within the range of 18 to 32 kg\u002Fm2 (inclusive)\n* In good general physical and mental health as evaluated through a comprehensive clinical assessment\n* Vital signs at screening and pre-inoculation within normal clinical range\n* Electrocardiograph (ECG) without significant abnormalities, including: QTcF ≤450 ms for males, QTcF ≤470 ms for females, PR interval ≤210 ms\n\nLaboratory Criteria:\n\n* O negative blood type\n* Haemoglobin, white cell count and platelet levels within normal laboratory ranges\n* Ferritin, creatinine and alanine aminotransferase (ALT) within normal laboratory ranges\n* No clinically significant abnormality in coagulation or clotting\n* Normal G6PD enzyme activity levels as defined by the parameters of the specific quantitative G6PD test performed at screening\n* Negative for blood borne viruses, including Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-lymphotropic virus type 1 (HTLV); and other blood borne pathogens including West Nile Virus (WNV), Babesia species, Treponema pallidum, and Trypanosoma cruzi\n\nCriteria specific to female participants:\n\n* Post-menopausal for at least 1 one year, post-hysterectomy, or bilateral oophorectomy with a correlating follicle stimulating hormone (FSH) level.\n\nOR\n\n* Females of childbearing age have a negative beta-human chorionic gonadotrophin (b-HCG) pregnancy test (urine or serum) on day of enrolment and prior to CHMI inoculation and agreement to use effective birth control through the duration of the study.\n\nEXCLUSION CRITERIA:\n\n* Participant lives alone and is unable provide contact details of a support person who is aware of the individual's participation in the study and is available to provide assistance if required\n* Participation in any investigational product study within the 12 weeks preceding inoculation\n* Positive urine drug test at screening or on the day of malaria inoculation unless there is an explanation acceptable to the Investigator (e.g. the volunteer has stated in advance that they consumed a prescription or over-the-counter product which contained the detected drug) and\u002For the volunteer has a negative urine drug screen on retest by the pathology laboratory\n* Positive alcohol breath test at screening or on the day of malaria inoculation\n\nMalaria History:\n\n* Any previous history of malaria infection, including participation in a malaria research study\n* Receipt of a malaria vaccination at any time, including as part of a research study\n* Travelled to or lived (more than two weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region over the course of the study\n* Lived for more than one year in a malaria-endemic region in the past 10 years\n* Lived in a malaria-endemic region for more than 10 years inclusive\n\nClinical History:\n\n* Anyone who is pregnant, breastfeeding or planning pregnancy during the study period\n* History of severe allergic reaction, including angioedema or anaphylaxis\n* Receipt of any live attenuated vaccines within 21 days prior to enrolment\n* Has ever received a blood transfusion\n* Use of blood products or immunoglobulins within the previous 6 months\n* Without good peripheral venous access\n* Clinical history of: Sickle cell disease, sickle cell trait or other haemoglobinopathies; Splenectomy or fuctional asplenia; Skeeter syndrome or anaphylactic response to mosquito bites\n* Known intolerance, hypersensitivity or other contraindication to artemether or other artemisinin derivatives, lumefantrine, atovaquone, proguanil, primaquine, or artesunate or any of its excipients\n* Use or planned use of any drug, including antibiotics, with antimalarial activity four weeks prior to inoculation\n* Use of any of the following drugs: Anticoagulants (within 14 days of enrolment); Systemic corticosteroids (within 3 months of enrolment); Any prescription or non-prescription drugs, and or supplements that in the opinion of the investigator would jeopardise the safety of the volunteer\n* Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, infectious diseases, psychiatric disorders, heart disease, or cancer\n\nClinical Risk:\n\n* Evidence at screening of increased cardiovascular disease risk (defined as \\>10%, 5-year risk for those greater than 35 years of age), as determined by the Australian Absolute Cardiovascular Disease Risk Calculator","18 Years","55 Years",{"count":91,"type":21},2,[93],"PHASE1","The goal of this clinical trial is to learn if the genetically-modified malaria parasite NF54\u002FiGP3 will safely infect humans with malaria. The investigators will also determine how the parasite grows in humans, and the effect of anti-malarial drugs.\n\nResearchers will use a controlled human malaria infection (CHMI) model to infect participants with malaria to observe the development of the disease, collect malaria-infected blood, and then treat the participants to cure the malaria infection.\n\nThe collected malaria-infected blood will be used to create a frozen stock of malaria parasites for use in future research.",[28,29,30],[97,98,99],"SWITCH","NF54\u002FiGP3","Plasmodium falciparum","2025-03-11",{"date":102,"type":41},"2025-03-18",{"date":104,"type":21},"2025-07",{"date":106,"type":21},"2026-07",{"name":108,"class":48},"University of Melbourne"]